SCHEMBL15629441

SCHEMBL15629441

COc1cccc2c1NC(=O)C(N)N=C2c1ccc(C(F)(F)F)cn1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTCH1 P46531 8/20 0.61
NOTCH3 Q9UM47 5/20 0.61
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM1A O60341 1/20 0.41
HCRTR1 O43613 6/20 0.39
RBPJ Q06330 3/20 0.38
HCRTR2 O43614 5/20 0.37
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
STK10 O94804 1/20 0.34
SLK Q9H2G2 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
TNKS O95271 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
PARP2 Q9UGN5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15608394 1.00 NOTCH1 (0.61) NOTCH1NOTCH3TSHRSMN1; SMN2KDM1A
SCHEMBL15629602 0.85 NOTCH1 (0.57) NOTCH1NOTCH3KDM1ARBPJSTK10
SCHEMBL15608442 0.85 NOTCH1 (0.57) NOTCH1NOTCH3KDM1ARBPJSTK10
SCHEMBL18174929 0.82 NOTCH1 (0.48) NOTCH1NOTCH3SMN1; SMN2RBPJSTK10
SCHEMBL23197996 0.77 NOTCH1 (0.66) NOTCH1NOTCH3RBPJ
SCHEMBL29412714 0.77 NOTCH1 (1.00) NOTCH1NOTCH3RBPJ
SCHEMBL15608342 0.77 NOTCH1 (1.00) NOTCH1NOTCH3RBPJ
SCHEMBL15608343 0.77 NOTCH1 (1.00) NOTCH1NOTCH3RBPJ
SCHEMBL23197997 0.77 NOTCH1 (1.00) NOTCH1NOTCH3RBPJ
SCHEMBL15622381 0.76 NOTCH1 (0.49) NOTCH1NOTCH3RBPJ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897945-B1 BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-12-21 EP disclosed
US-8999918-B2 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-07 US disclosed
WO-2014047372-A1 BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-27 WO disclosed
US-20140087992-A1 BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF BRISTOL-MYERS SQUIBB COMPANY 2014-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140087992-A1 BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF CNR1, ROR1, RORB NOTCH1 71/4885NOTCH3 47/4885TSHR 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.